Skip to main content
Retour
Watch Compare

Regen BioPharma Inc

Qualité des données : 100%
Également cotée sous RGBPP OTC
RGBP
OTC Manufacturing Chemicals
0,00 €
0,00 € (0,00%)
Cap. Boursière: 106 159,0
6 months return
—
Momentum
Neutral
5Y revenue growth
40,22%

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Revenue grew 40,22% annually over 5 years — strong growth
Negative free cash flow of -515 153,0
Revenue growth is decelerating — 1Y growth trails 5Y average by 40,22%

Price History

Croissance

Revenue Growth (5Y)
40,22%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)0,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
N/A
ROICN/A
Net Margin-730,03%
Op. Margin-350,35%

Sécurité

Debt / Equity
N/A
Current Ratio0,03
Interest Coverage-5,20

Valorisation

PE (TTM)
-0,06
Au-dessus de la moyenne du secteur (-1,49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1605 pairs)
Métrique Action Médiane du Secteur
P/E -0,1 -1,5
P/B — 1,6
ROE % — -54,5
Net Margin % -730,0 -41,5
Rev Growth 5Y % 40,2 1,8
D/E — 0,3

Objectif de Cours des Analystes

Consensus des analystes : objectif moyen vs prix actuel et notation.

Aucune couverture d'analyste disponible

Estimations de Bénéfices

Prévisions d’EPS et de chiffre d’affaires par période. Annuel = exercices ; trimestriel = prochains trimestres.

Période BPA Est. CA Est. Analystes
FY2026 — 331 704,78 —

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0,00% Revenue Growth (3Y) 36,72%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 40,22% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 236 561,0 Net Income (TTM) -1,73 M
ROE N/A ROA -795,99%
Gross Margin N/A Operating Margin -350,35%
Net Margin -730,03% Free Cash Flow (TTM) -515 153,0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,03
Interest Coverage -5,20 Asset Turnover 1,09
Working Capital -6,57 M Tangible Book Value -6,57 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,06 Forward P/E N/A
P/B Ratio N/A P/S Ratio 0,45
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -485,27%
Market Cap 106 159,0 Enterprise Value 101 581,0
Per Share
EPS (Diluted TTM) 0,07 Revenue / Share 0,00
FCF / Share 0,00 OCF / Share 0,00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 29,83%
SBC-Adj. FCF N/A Growth Momentum -40,22

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 236 561,0 236 560,0 126 560,0 125 517,0 61 194,0
Net Income -1,27 M -668 255,0 1,16 M 2,44 M -6,77 M
EPS (Diluted) -0,05 -0,16 0,29 — —
Gross Profit — — — — —
Operating Income -338 540,0 -417 221,0 -686 950,0 -339 605,0 -200 771,0
EBITDA — — — — —
R&D Expenses 11 725,0 153 685,0 212 297,0 158 138,0 36 704,0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 158 286,0 72 445,0 58 584,0 138 720,0 316 013,0
Income Tax 0,0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 274 628,0 161 084,0 353 617,0 559 002,0 1,21 M
Total Liabilities 6,56 M 5,38 M 5,46 M 8,60 M 14,70 M
Shareholders' Equity -6,28 M -5,22 M -5,10 M -8,04 M -13,49 M
Total Debt — — — — —
Cash & Equivalents 69 555,0 716,0 — 51 204,0 727 162,0
Current Assets 274 628,0 143 351,0 131 037,0 336 422,0 994 124,0
Current Liabilities 6,56 M 5,38 M 5,31 M 8,60 M 14,70 M